Cargando...
Public funding for transformative drugs: the case of sofosbuvir
The approval of sofosbuvir (Sovaldi) in 2013 transformed chronic hepatitis C virus (HCV) care, but its high cost was criticized in part because of reports of substantial public involvement in its development. We developed a methodology to assess the public’s contribution through the National Institu...
Gardado en:
| Publicado en: | Drug Discov Today |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Published by Elsevier Ltd.
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7528745/ https://ncbi.nlm.nih.gov/pubmed/33011345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2020.09.024 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|